![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 01, 2020 2:03:32 AM
Findings Demonstrate Ability of 17 FDA Approved Drugs to Inhibit SARS-CoV-2 (Coronavirus)
(PRNewsfoto/AIkido Pharma Incorporated)
NEWS PROVIDED BY
AIkido Pharma Inc.
Sep 11, 2020, 09:00 ET
SHARE THIS ARTICLE
NEW YORK, Sept. 11, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Journal of Virology. The publication cites that 17 of the 20 FDA-approved drugs studied inhibit SARS-CoV-2 at non-cytotoxic concentrations.
Mr. Anthony Hayes, CEO of AIkido stated, "The publication of a peer-reviewed study in a highly-revered journal represents additional validation of University of Maryland, Baltimore's (UMB) antiviral platform. The results clearly articulate the technology we have optioned from the university, and we are encouraged by the opportunities we may be able to pursue with the platform".
In the article, which was co-authored by investigators from the University of Maryland School of Medicine, 17 of the 20 FDA approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV inhibit SARS-CoV-2 at non-cytotoxic concentrations suggesting these may have pan-anti-coronaviral activity.
The full article is available at https://jvi.asm.org/content/early/2020/08/13/JVI.01218-20.
The Company previously executed a Master License Agreement with UMB for specific antiviral compounds discovered by UMB that seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The Company previously executed a Sponsored Research Agreement with UMB to support the development of the technology.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM